President Donald Trump's drug price containment plan blames the 340B drug discount program in part for high drug prices, and asks for feedback in a number of areas including how the program's growth affects list prices and insurers, whether the definition of a 340B patient should be changed and how to better prohibit duplicate discounts. Both the definition of a patient and duplicate discounts were covered in guidance initially published by the Obama administration that Trump's Health Resources and Services...